The proposal is aimed to improve the pharmacological effects of low-molecular weight heparins (LMWH). This project is a collaborative effort of four research groups, including Dr. Jian Liu (University of North Carolina) Dr. Robert Linhardt (Rensselaer Polytechnic Institute), Dr. Edward Harris (University of Nebraska, Lincoln) and Dr. Jawed Fareed (Loyola University Medical Center). LWMH is a widely used anticoagulant drug to treat thrombotic disorders. The currently marketed LMWH drugs are a mixture of sulfated poly-/oligo-saccharides, which are vulnerable to contamination and batch-to-batch variability. We plan to synthesize structurally homogeneous LMWH to eliminate the structural heterogeneity. The new LMWH constructs should display consistent anticoagulant activity, improved sensitivity to protamine neutralization, and controlled metabolic pathway. The synthesis of homogeneous LMWH will be completed using a chemo enzymatic approach. The pharmacological effects of the products will be evaluated in mouse and primate models. The success of this project will optimize the structures of heparin-based drugs with improved safety and efficacy.

Public Health Relevance

Low-molecular weight heparin is a commonly used anticoagulant drug. Currently, low-molecular weight heparin is prepared from the degradation of heparin that is isolated from animal tissues. It has been known that animal-sourced heparin is vulnerable to contamination. This project is aimed to design and synthesize structurally homogeneous low-molecular weight heparins to improve its pharmacological effects as well as eliminate the need for animal-sourced heparin.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Sarkar, Rita
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Pharmacy
Chapel Hill
United States
Zip Code
Pellock, Samuel J; Walton, William G; Biernat, Kristen A et al. (2018) Three structurally and functionally distinct ?-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem 293:18559-18573
Xu, Ding; Arnold, Katelyn; Liu, Jian (2018) Using structurally defined oligosaccharides to understand the interactions between proteins and heparan sulfate. Curr Opin Struct Biol 50:155-161
Stancanelli, Eduardo; Elli, Stefano; Hsieh, Po-Hung et al. (2018) Recognition and Conformational Properties of an Alternative Antithrombin Binding Sequence Obtained by Chemoenzymatic Synthesis. Chembiochem :
Xiao, Yiming; Li, Miaomiao; Larocque, Rinzhi et al. (2018) Dimerization interface of osteoprotegerin revealed by hydrogen-deuterium exchange mass spectrometry. J Biol Chem 293:17523-17535
Lin, Yi-Pin; Li, Lingyun; Zhang, Fuming et al. (2017) Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease. Microbiology 163:1759-1766
Wang, Zhangjie; Hsieh, Po-Hung; Xu, Yongmei et al. (2017) Synthesis of 3-O-Sulfated Oligosaccharides to Understand the Relationship between Structures and Functions of Heparan Sulfate. J Am Chem Soc :
Xu, Yongmei; Moon, Andrea F; Xu, Shuqin et al. (2017) Structure Based Substrate Specificity Analysis of Heparan Sulfate 6-O-Sulfotransferases. ACS Chem Biol 12:73-82
Meneghetti, Maria Cecília Zorél; Gesteira Ferreira, Tarsis; Tashima, Alexandre Keiji et al. (2017) Insights into the role of 3-O-sulfotransferase in heparan sulfate biosynthesis. Org Biomol Chem 15:6792-6799
Xu, Yongmei; Chandarajoti, Kasemsiri; Zhang, Xing et al. (2017) Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins. Sci Transl Med 9:
Schultz, Victor; Suflita, Mathew; Liu, Xinyue et al. (2017) Heparan Sulfate Domains Required for Fibroblast Growth Factor 1 and 2 Signaling through Fibroblast Growth Factor Receptor 1c. J Biol Chem 292:2495-2509

Showing the most recent 10 out of 85 publications